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Background: The meninges (arachnoid and pial membranes) and associated vasculature (MAV) and choroid plexus
are important in maintaining cerebrospinal fluid (CSF) generation and flow. MAV vasculature was previously
observed to be adversely affected by environmentally-induced hyperthermia (EIH) and more so by a neurotoxic
amphetamine (AMPH) exposure. Herein, microarray and RT-PCR analysis was used to compare the gene expression
profiles between choroid plexus and MAV under control conditions and at 3 hours and 1 day after EIH or AMPH
exposure. Since AMPH and EIH are so disruptive to vasculature, genes related to vasculature integrity and function
were of interest.
Results: Our data shows that, under control conditions, many of the genes with relatively high expression in both
the MAV and choroid plexus are also abundant in many epithelial tissues. These genes function in transport of
water, ions, and solutes, and likely play a role in CSF regulation. Most genes that help form the blood–brain barrier
(BBB) and tight junctions were also highly expressed in MAV but not in choroid plexus. In MAV, exposure to EIH
and more so to AMPH decreased the expression of BBB-related genes such as Sox18, Ocln, and Cldn5, but they
were much less affected in the choroid plexus. There was a correlation between the genes related to reactive
oxidative stress and damage that were significantly altered in the MAV and choroid plexus after either EIH or AMPH.
However, AMPH (at 3 hr) significantly affected about 5 times as many genes as EIH in the MAV, while in the
choroid plexus EIH affected more genes than AMPH. Several unique genes that are not specifically related to
vascular damage increased to a much greater extent after AMPH compared to EIH in the MAV (Lbp, Reg3a, Reg3b,
Slc15a1, Sct and Fst) and choroid plexus (Bmp4, Dio2 and Lbp).
Conclusions: Our study indicates that the disruption of choroid plexus function and damage produced by AMPH
and EIH is significant, but the changes may not be as pronounced as they are in the MAV, particularly for AMPH.
Expression profiles in the MAV and choroid plexus differed to some extent and differences were not restricted to
vascular related genes.
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The choroid plexus and the meninges (arachnoid and
pial membranes) and associated vasculature (MAV) form
an entity that is of utmost importance in regulating
brain blood flow and cerebrospinal fluid (CSF) integrity.
As well, they are critical in maintaining the neuronal
integrity of the brain, particularly the cerebral hemispheres
[1-10]. This is the case when damage to vasculature within
specific brain regions in the cerebral hemispheres occurs
from neurotoxic doses of amphetamine (AMPH) in labora-
tory animals [11-14] and the abuse or illegal use of AMPH
and methamphetamine (METH) in humans [15-19]. Unlike
other well characterized cerebrovascular insults [6,8,20-23],
much less is known about how amphetamines compromise
the vasculature in MAV, the choroid plexus, and areas
within the cerebral hemispheres. Our previous studies
[24,25] examined how amphetamines adversely affect MAV
vasculature in laboratory animals. However, the effects of
neurotoxic doses of amphetamine on choroid plexus
function have not been previously addressed.
In the MAV, AMPH and METH directly release
norepinephrine from the terminals of adrenergic input to
the arteries and arterioles in the pial layer causing vaso-
constriction and bypassing neuronal impulse regulation
of release from the sympathetic ganglia, which normally
auto-regulates cerebral blood flow (CBF) [2-4]. Although
this may initially be responsible for reduced CBF in
laboratory animals, it is not the only cause [13]. In a
previous study, we observed increased changes in the
expression of genes related to regulating CBF, including
endothelin1 (Edn1) and nitric oxide synthase (Nos1), that
may be initiated to overcome the AMPH dysregulation of
CBF; the lack of increased vasointestinal peptide (Vip)
may be a deficiency induced by AMPH [24]. Not only
does neurotoxic AMPH exposure cause a prominent
alteration in regulation of vascular tone, it also disrupts
the expression of genes related to angiogenesis and pro-
duces a significant endoplasmic reticulum stress response
(ERSR) [24,25]. As of yet, it is not specifically known how
neurotoxic exposures to AMPH and METH affect choroid
plexus vasculature and CSF production.
In the current work, efforts were taken to identify
genes in MAV, as well as the choroid plexus, that are
responsible for regulating CSF composition and flow
because alteration in CSF function could lead to significant
adverse effects on brain function [6,8]. Recent laboratory
animal research indicates that most CSF exits the brain
through the lymphatic system around the cranial nerves
rather than the arachnoid villi residing at the most dorsal
aspect of the meninges [5,26-28]. This suggests a CSF flow
more dorsally directed, which could well necessitate the
MAV playing a more prominent role in regulating CSF flow
and composition. As a means of trying to identify genes
involved in the regulation of CSF flow and composition, wefirst compared the global gene expression profiles under
control conditions in the neuronal-rich tissues striatum and
parietal cortex to those in the vascular-rich tissues choroid
plexus and MAV. This enabled the identification of genes
with 15-fold or greater expression in MAV and choroid
plexus compared to striatum and parietal cortex. In
addition to identifying genes related to CSF composition
and flow, our study further aimed at identifying genes
with much higher expression in MAV and choroid plexus
than in striatum and parietal cortex that could be of great
importance in other specific functions (not CSF) of MAV
and choroid plexus and possibly more likely to be more
significantly affected by AMPH.
Additionally, we examined gene expression changes
resulting from environmentally-induced hyperthermia
(EIH), since the neurotoxicity [29-33] and vascular
effects [11,12,14,31] of AMPH and METH are highly
temperature-dependent. Importantly, hyperthermia alone
adversely affects the vasculature of the brain [34-37]. As
well, EIH toxicity in rats has many similar characteristics
to heat stroke in humans, which has been reported to have
neurotoxic and vascular effects [34-36,38]. However, un-
like AMPH and METH, EIH does not produce dopamine
terminal damage or diffuse neurodegeneration in the
parietal cortex, limbic cortex, and thalamus. Also, EIH
does not arrest angiogenesis or elevate endothelial nitric
oxide synthase1 (Nos1) in MAV as does AMPH [24,25].
As with neurotoxic AMPH and METH exposures, little is
known regarding the effects of EIH on choroid plexus
vasculature and CSF production.
Through the use of oligo array and RT-PCR technologies,
the present study evaluates global gene expression changes
resulting from the adverse and damaging effects of neuro-
toxic exposures of AMPH and EIH in rat mRNA from the
MAV and choroid plexus. Gene expressions were measured
from RNA generated from tissues obtained from our previ-
ous studies [24,25] and from additional new RNA samples
obtained from the choroid plexus and MAV. Particular
interest was focused on comparing fold-changes of genes
related to vascular tight junctions and the blood–brain
barrier (BBB) in MAV and choroid plexus because a loss of
integrity of tight junctions in these two structures would
likely lead to significant adverse effects. One of the main
goals of the study is to identify genes in MAV and choroid
plexus that are not necessarily known to affect vascular
function and genes that are not well characterized.
Results
In the current study, we present the effects of AMPH
and EIH on global gene expression levels in the choroid
plexus via array analysis (found at: GEO, NCBI; data
file GSE29733) and compare these effects with those
induced in the MAV, striatum, and parietal cortex
(GEO, NCBI; data file GSE23093) on a genome-wide
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further evaluated/confirmed using RT-PCR for all four
tissues/brain regions. Changes in body temperature and
behavior have previously been reported for control, EIH,
and AMPH exposed animals [24,25]. The additional rats
dosed for obtaining more choroid plexus and MAV tissue
samples had the same temperature profiles as those previ-
ously exposed to AMPH and EIH (data not shown). Array
and RT-PCR data for the choroid plexus have not been
reported previously nor has the global gene expression in
choroid plexus ever been compared to that in MAV,
striatum, or parietal cortex. Changes in MAV, striatum,
or parietal cortex expression after either EIH or AMPH
exposure for some genes known to regulate vascular
tone, angiogenesis, and endoplasmic reticulum stress
response (ERSR) have been reported in the two afore-
mentioned manuscripts. As well, a manuscript/videoTable 1 Putative function of genes with increased expression
striatum and parietal cortex under control conditions
Choroid plexus expression relative to
striatum and parietal cortex expression
NCBI gene symbols
> 50-fold Col8a1, Esm1, Glycam1, Lect1
> 50-fold A2m, Pla2g5, Xcl1
> 50-fold Adipoq, Pon1, Pon3
> 50-fold Cldn1, Crb3, Fmod, Kla, Steap1
> 50-fold Aqp1, Atp4a, Clic6, Kcne2, Kcnj1
Slco1a5, Ttr, Trpm3
> 50-fold Cdkn1c, Folr1, Igfbp2, Mpzl2,
> 50-fold Cox8h, Efhb, Epn3, Fscn2, Klc3,
30 to 50-fold Lepr, Mdk, Ogn, Tnni2
30 to 50-fold Cd74a, Klra5, Nphs1, RT1-Da, S
30 to 50-fold Cldn2, Dcn, Lama2, Lgals3bp,
30 to 50-fold Slc4a2, Slc26a7
30 to 50-fold Apoa2, Lrat
30 to 50-fold Msx3, NTF4, Wfikkn2
30 to 50-fold Atp11c, Copz2, Dhrs7c, Dmrt3,
Pdlim2, Phactr2, Sah, Scara5, S
15 to 30-fold Ace, Anxa2a, Cox8h, Itgb6, Trim
15 to 30-fold Cmtm8, Ctsc, Igsf1, RT1-Db1
15 to 30-fold Adamtsl4, Col9a3, Dsp, Loxl1, M
15 to 30-fold Fxyd1, Slc12a4, Slc16a12, Slc19a1
15 to 30-fold Agpat2, Enpp2, Gprc5c, Rbp2
15 to 30-fold Cdkn1a, Dab2, Igf2, Nr1i2, Prrx
15 to 30-fold Akap14, Capn3, Capsl, Ccdc37, D
Iqcg, Kpl2, Lhb, Mesp1, Nudt7, O
Pqlc3, Tsga2, Sod3, Spata6, Spin
* Genes included in the table must have been more than 15-fold above expression
at least 5-fold above the background level. Also, expression must have been relativ
the mean. The lower of the two ratios (choroid plexus/striatum or choroid plexus/p
using NCBI Entrez Gene.
aGenes found in endothelial cells that also likely play a major role in mediating imm
Bold font indicates gene expression was also at least 15-fold greater in MAV compa
Underlined font indicates gene expression was also at least 10- to 15-fold greater inpresentation [39], which shows dissection methods for the
MAV, contains a table showing the large fold-differences
in MAV gene expression with expression in striatum and
cortex. However, complete analysis and comparison of the
global gene expression in MAV under control, EIH, or
AMPH conditions have never been presented, and MAV
gene expression has not been previously compared with
choroid plexus.
Control expression profiles in choroid plexus, MAV,
striatum and parietal cortex
Global gene expression under control conditions
Gene expression data in the control animals were used
to generate Additional file 1: Table S1, which presents
summary statistics (mean and standard deviation) of gene
expression data (>11,000 genes) from the MAV, striatum,
parietal cortex, and choroid plexus. Table 1 shows genes inof 15-fold* or more in choroid plexus compared to
Tissue specificity or reported function(s)
, Thbs2 Vasculature & Heart
Immune System
Retinoic Acid & Lipid Processing
, Tmem27 Extracellular Matrix & Cell-Cell Junctions
3, Slc4a5, Slc5a5, Slc16a8, Ion & Solute Transport & Homeostasis
Msx1,Otx2, Sostdc1 Development & Transcription Regulation
Krt18, Scgb1c1 Unknown & Miscellaneous
Vasculature & Heart
erpinb1a Immune System
Rsph4a Extracellular Matrix & Cell-Cell Junctions
Ion & Solute Transport & Homeostasis
Retinoic Acid & Lipid Processing
Development & Transcription Regulation
F5, Klk4, Krt8, Nt5dc2,
pag8,
Unknown & Miscellaneous
63 Vasculature & Heart
Immune System
mp14, Prelp, Sulf1 Extracellular Matrix & Cell-Cell Junctions
, Slc25a30, Sned1 Ion & Solute Transport & Homeostasis
Retinoic Acid & Lipid Processing
2, Sfrp1, Zic4 Development & Transcription Regulation




in the choroid plexus compared to both the striatum and parietal cortex and
ely consistent across individual control animals so that the S.D. was less than
arietal cortex) for each gene was used for grouping. Genes were categorized
une responses.
red to both the striatum and parietal cortex.
MAV compared to both the striatum and parietal cortex.
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in choroid plexus than in striatum and parietal cortex
under control conditions. Genes in MAV that have a 15-
fold higher expression than the striatum and parietal cortex
can be found in [39] and Additional file 2: Table S2. Genes
with a 15-fold or higher expression level in MAV and
choroid plexus, relative to the striatum and parietal
cortex (neuronal-rich tissues), were identified as being
genes of particular importance to the function of these
neuronal-sparse tissues. Genes with higher expression
(5-fold or more) in circulating blood (GSE29733;
present in leukocytes or reticulocytes) than in the
MAV and choroid plexus were not included in this list
to exclude the possibility that the high expression
levels in the MAV and choroid plexus were due to
residual blood in these tissues. There was a significant
number of genes with 15-fold or higher expression in
the MAV and the choroid plexus compared to the striatum
and parietal cortex that were directly related to the vascular
system and/or the immune system, but they were not in
the majority (Table 1 and Additional file 2: Table S2). A
number of the genes with very large fold changes were:
1) extracellular matrix proteins (not specifically related
to vasculature), 2) solute transporters, and 3) proteins
involved in lipid and retinoic acid metabolism. As well,
a few growth and differentiation genes or transcription
factors were found. The overlap in the genes with a
15-fold or greater expression in MAV and choroid
plexus relative to neuronal tissues was over 50% (60% for
10-fold or greater genes) (Table 1).
Levels of vasculature-related genes in choroid plexus, MAV,
striatum, and cortex
The mRNA expression levels of genes normally ascribed
to be present in almost all types of vascular endothelium
(not just BBB or tight junction related), such as intercellular
adhesion molecule 1 (Icam1), kinase insert domain receptor
(Kdr/Vegfr2), nitric oxide synthase 3 (Nos3), and vascular
cell adhesion molecule 1 (Vcam1) were 5- to 10-fold greater
in MAV than in the parietal cortex and striatum under
control conditions (Table 2). These higher levels suggest
that there is likely a 5- to 10-fold greater vascular content
in the MAV compared to striatum and parietal cortex.
In contrast, in the choroid plexus most of the vascular
associated genes that were not linked to tight junctions
or the BBB were at the same level as the neuronal
tissues, with the exception of Icam1 and Kdr levels
which were in the MAV range. This was also true for
most of the genes related to angiogenesis (e.g., Ctgf,
Timp1 Vegfc, Anpep, Col18a1); only Mmp2 and Akt1
were at or above MAV levels in the choroid plexus
(Table 2). In contrast, genes related to the ERSR pathways
were expressed at very similar levels in the MAV and
choroid plexus (Additional file 1: Table S1).Under control conditions, the expression of many genes
associated with tight junctions or BBB that are present in
the vasculature of neuronal-rich tissues, such as the parietal
cortex and striatum, were as high in MAV even if it is
assumed that the vasculature in MAV was 5- to 10-fold
greater (previous paragraph). However, the “relative” ex-
pression levels of claudin 3 (Cldn3), tight junction protein 2
(Tjp2), and aquaporin 4 (Aqp4) in MAV may be many-fold
below that of parietal cortex and striatum due to MAV hav-
ing such a greater proportion of vasculature. The expres-
sion of solute carrier family 9 (sodium/hydrogen exchanger,
Slc9a2), a gene implicated in tight junctions [40], is higher
than expected in MAV. The choroid plexus expressed high
levels of some genes that are involved in tight junctions
such as Ocln, Cldn1, Cldn2, Cldn9, F11r, Jam3, and Tpj3,
but expression profiles of the various tight junction genes
in this tissue differed somewhat from MAV and even more
so from striatum and parietal cortex (Table 2).
Effects of AMPH and EIH on gene expression
Genes related to vascular tone, ERSR, angiogenesis, and
tight junctions
In the choroid plexus, the effects of EIH and AMPH on
many genes related to vascular tone (e.g., Edn1, Nos3,
and Vip) and angiogenesis did not reach significance,
with the exception of Adora1a and Adora1b (Table 3).
In contrast, in the MAV, EIH and/or AMPH significantly
increased Edn1, Nos3, and Vip levels but not Adora1a
and Adora1b ([24], Additional file 3: Table S3). Also,
more BBB genes were differentially affected in MAV
compared to choroid plexus after EIH and AMPH
exposure within 3 hr. Sox18, Ocln, Cldn5, and Jam2
expressions were prominently decreased by EIH and/or
AMPH (in most cases to a greater extent by AMPH) in
MAV (Table 4), as well as in the striatum and parietal
cortex (data not shown). However, none of these four
genes were significantly affected in the choroid plexus
(Table 4). Array data indicated that Esam was increased
by AMPH in the MAV, striatum, and parietal cortex,
while in the choroid plexus both AMPH and EIH tended
to increase Esam expression (Table 4). RT-PCR analysis
confirmed the significant Esam increases in the striatum
and cortex but not in the MAV (Table 5). Array data
analysis indicated that Tjp1, Tjp2, and Tjp3 were not
affected in choroid plexus or MAV by EIH or AMPH
(Table 3 and Additional file 3: Table S3).
The expression of Ctgf and Timp1, which are genes
related to angiogenesis, did increase in the choroid
plexus after AMPH like it did in the MAV (Table 3, [24]
and Additional file 3: Table S3). The decreases in the
angiogenesis-related or tissue remodeling genes Mmp2,
Mmp14, and Mmp16 were not significant (Table 3) and
not as prominent in the choroid plexus as the MAV
(Additional file 3: Table S3, Additional file 4: Table S4
Table 2 Normalized expression of selected genes in control animals for all four brain regions determined by oligo
array analysis
Brain region
MAV Parietal cortex Striatum Choroid plexus
NCBI gene 3 hr control 3 hr control 3 hr control 3 hr control
Symbol Mean ± S.D. Mean ± S.D. Mean ± S.D. Mean ± S.D.
Anpep 441.7 57.8 52.9 11.4 34.6 9.3 83.0 12.9
Akt1 666.1 62.8 1185.9 88.1 1164.0 169.1 983.6 88.1
Aqp1 2433.0 721.3 33.9 2.6 31.0 5.4 8576.6 513.3
Aqp4 70.0 27.4 42.2 6.5 169.7 39.6 35.7 24.6
Cldn1 446.5 305.9 8.6 3.8 7.5 2.1 2075.5 235.0
Cldn2 46.9 40.5 6.3 3.2 7.0 3.5 350.6 55.1
Cldn3 68.0 13.0 127.9 29.5 82.4 10.7 327.1 4.7
Cldn5 9721.0 2380.3 2222.5 784.9 2505.1 461.6 274.4 74.7
Cldn9 2248.0 380.2 147.3 34.4 364.0 86.0 1335.8 121.8
Col18a1 1523.7 335.7 48.4 16.1 183.0 33.1 148.9 44.7
Ctgf 4842.1 1174.6 666.7 190.5 540.2 188.6 224.6 47.2
Icam1 1186.5 151.9 101.3 12.1 84.9 8.1 508.5 18.2
F11r 1134.3 205.4 176.3 5.9 167.3 20.5 1602.3 200.7
Jam3 418.9 113.0 295.4 34.3 357.6 53.9 1318.4 94.0
Kdr 12737.6 1911.1 1310.9 319.1 1604.2 272.0 6323.5 874.5
Mmp2 1003.8 609.1 96.7 18.7 105.5 21.7 7657.0 986.9
Mmp14 5519.5 1293.1 195.9 86.8 277.3 77.2 6744.9 1065.3
Nos3 757.9 157.5 174.6 27.1 145.5 14.6 91.4 25.4
Ocln 1611.4 291.8 183.3 26.2 253.5 13.1 3503.3 311.4
Timp1 7226.9 1483.0 260.3 50.7 224.2 45.3 888.1 88.7
Tjp2 337.2 60.5 291.6 18.9 336.5 16.9 286.4 49.5
Tjp3 183.4 138.9 39.5 7.3 97.9 5.7 1427.6 217.9
Vcam1 12434.4 2077.7 2604.2 222.6 3787.3 356.9 2660.5 195.6
Vegfc 1750.4 333.1 658.7 129.1 310.4 29.8 548.1 33.5
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choroid plexus was similar to MAV, with multi-fold
increases seen in Hspa5, Atf3, Atf4, Nfkbia, and Nfkb2
(Table 3, Additional file 3: Table S3). As well, expression
of the protein di-isomerases encoding genes Pdia3, Pdia4,
and Pdia6 was increased similarly by AMPH and EIH in
both MAV and choroid plexus (Table 3, Additional file 3:
Table S3 and Additional file 4: Table S4).
Effects of AMPH and EIH on genes in MAV that are not
directly related to vasculature
Array expression data indicated significant expression
changes within the MAV due to either EIH or AMPH
when compared to control at the 3 hr time point
(Additional file 3: Table S3). At the 3 hr time point,
significant differences were found in the expression
level of 265 genes (FDR = 0.10) when comparing EIH/
control and 1,129 genes (FDR = 0.10) when comparingAMPH/control. Core analysis with the IPA software found
that the gene expression patterns clearly indicate that both
EIH and AMPH produced significant increases in genes
involved in reactive oxygen species (ROS) and inflamma-
tory responses with some indication that apoptosis may
have occurred (data not shown). When comparing AMPH
to EIH at 3 hr, a total of 70 genes (FDR = 0.10) were
differentially expressed (Table 6). IPA analysis suggests
that these genes are involved in cancer, reproductive system
disease, gastrointestinal, cardiovascular, and immunological
inflammatory diseases.
Three genes, linked to pancreatitis and cancer, the
regenerating islet-derived 3 alpha, beta and gamma
(Reg3a, Reg3b and Reg3g), were increased by more than
100-fold by AMPH within 3 hr, but not by EIH (Table 5
and Table 6). These genes were not significantly affected
in the choroid plexus at the 3 hr time point (Table 5 and
Table 7). At 1 day after AMPH, Reg3a, Reg3b, and Reg3g
Table 3 Genes in choroid plexus significantly affected
3 hr after either AMPH or EIH compared to control group
(FDR = 0.10)
AMPH group expression relative
to control
EIH group expression relative
to control
NCBI Gene Symbol Fold-Change NCBI Gene Symbol Fold-Change
Abcc8 3.39 Abcc8 1.79
Acat1 0.59 Abhd2_predicted 1.47
Adora2b 3.21 Adora2a 2.75
Ahsa2_predicted 5.27 Adora2b 3.7
Arg2 6.4 Ahsa2_predicted 6.6
Arid5a 3 Ak2 1.68
Atf3 7.69 Angptl4 2.27
Bag3 6.5 Ap1s2_predicted 2.03
Bmp4 4.52 Arg2 7.99
C1qr1 3.03 Arhgef5 1.65
Cables1_predicted 2.67 Arid5a 2.97
Cacybp 2.58 Armet_predicted 2.64
Cd14 2.05 Atf3 13.16
Cebpd 9.67 Atg16l1_predicted 2.1
Chordc1_predicted 2.63 Azi2 1.83
Ctgf 4.06 Bag3 12.93
Cxcl1 60.84 Bcl6_predicted 2.4
Cyr61 9.73 Bicd2 1.75
Dusp1 6.32 Birc3 2.49
Emr1 0.53 Bst2 2.7
Fkbp4 3.32 Btg1 1.84
Flrt2_predicted 2.67 Btg2 2.4
Fos 28.1 C1qr1 3
G0s2 0.29 Cables1_predicted 2.05
Gata1 4.86 Cacybp 2.72
Gda 3.26 Calr 1.63
Gjb2 0.19 Carhsp1 1.45
Has1 11.3 Cars_predicted 1.47
Hmox1 7.19 Cblb 1.6
Hspa1a 56.38 Ccl2 6.64
Hspa4l_predicted 2.74 Ccl7 2.28
Hspb1 12.83 Cd14 2.36
Hspca 3.23 Cd24 1.74
Hspcb 2.08 Cdx4_predicted 1.92
Hspd1 3.51 Cebpb 4.24
Hspe1 2.54 Cebpd 8.85
Hsph1 5.58 Cflar 3.01
Icam1 2.33 Chac1_predicted 2.86
Id4 3.21 Chordc1_predicted 2.69
Il1b 3.69 Creld2 2.72
Il1r2 9.89 Crem 1.82
Table 3 Genes in choroid plexus significantly affected
3 hr after either AMPH or EIH compared to control group
(FDR = 0.10) (Continued)
Il1rn 4.15 Cryab 3.4
Il6st 2 Ctgf 4.44
Inhbb 8.3 Cxcl1 55.72
Junb 6.14 Cxcl2 24.79
Litaf 2.29 Cxcr4 2.29
Lman2l_predicted 2.56 Cyr61 13.53
Nfkbia 2.24 Dapk3 1.56
Nr4a3 16.67 Ddit3 2.57
Ntel1 1.6 Ddx18 1.44
P4ha1 4.11 Ddx50 1.72
Phlda1 2.22 Dlc1 2
Dnaja1 2.26
Pla2g1b 3.48 Dnaja4 2.45
Plagl1 3.67 Dnajb1_predicted 4.68
Plod1 1.84 Dnajb11 1.85
Polg2_predicted 1.84 Dnajb4 2.39
Pspla1 2.47 Dnajb9 2.1
Rgs1 11.34 Dnajc3 1.51
Sectm1b 13.19 Dusp1 5.04
Serpine1 10.33 Dusp11 1.82
Serpinh1 2.56 Egr1 4.39
Slc5a3 2.06 Errfi1 3.75
Slco1c1 1.63 Ets2 1.81
Slpi 8.21 Exosc3_predicted 2
Sphk1 3.32 Fbln1_predicted 2.11
Spry1_predicted 4.04 Fbxl3 1.56
Stat3 1.83 Fbxo30 1.87
Stip1 2.62 Fgl2 5.87
Timp1 3.15 Fkbp4 3.77
Tmem63c_predicted 2.6 Flrt2_predicted 3.72
Tnfrsf12a 4.32 Fos 8.5
Trib3 2.82 Gadd45b 4.2
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http://www.biomedcentral.com/1471-2164/14/147expression was still elevated in the MAV (Table 5). Our
data also indicated that the intestinal hydrogen peptide
co-transporter (Slc15a1), follistatin (Fst), hyaluronan syn-
thase (Has1), secretin (Sct) and lipopolysaccharide binding
protein (Lbp) genes were also increased to a much greaterextent by AMPH than EIH in the MAV (Table 6). The
significance of the increases in these genes at the 3 hr time
point was verified with RT-PCR, with the exception of
Lbp (Table 5). At the 1 day time point, differences between
EIH and AMPH in the expression of Slc15a1, Fst, and Sct
were lesser in fold and not deemed statistically significant.
However, RT-PCR data indicated that the expression
levels of Sct, Has1, Fst, and particularly Lbp were signifi-
cantly greater after AMPH compared to EIH at the 1 day
time point (Table 5).
Approximately 272 genes, or 2.5% of the total number of
all the genes present on the oligo array, had 15-fold or
higher expression levels in the MAV relative to both the
striatum and parietal cortex (Additional file 2: Table S2).
Using this proportion, the expected number of differentially
expressed genes with high expression in the MAV at the
3 hr time (when comparing EIH/control and AMPH/
control) was computed. The expected (actual) counts for
EIH/control and AMPH/control are 7 (13) and 28 (61),
respectively. When comparing AMPH to EIH, two of
the differentially expressed genes were expected to
have high expression in MAV; however, the actual
count is 7. Therefore, we found the observed counts to
be higher than the expected counts in all three pairwise
treatment comparisons.
Effects of AMPH and EIH on genes not directly related to
vasculature in choroid plexus
Our choroid plexus oligo array data show that, at the
3 hr time point, EIH significantly affected the expression
of 208 genes (FDR = 0.10) when comparing EIH to con-
trol, while 73 genes differed between AMPH and control
(FDR = 0.10, Table 3). The gene expression patterns
indicate that both EIH and AMPH produced significant
similar increases in genes involved in ROS, inflammatory
responses and damage. Although relative to control both
AMPH and EIH dramatically altered gene expression in
the choroid plexus at the 3 hr time point, when the two
treatments were compared to each other, no genes
(FDR = 0.10) were found to be differentially affected
(Table 3). This would indicate that both AMPH and EIH
had very similar effects on choroid function at 3 hr. How-
ever, the sample size of four used in the array analysis may
have contributed for the lack of significant genes which
were differentially affected by AMPH compared to EIH.
Several genes with the greatest differential expression in
AMPH compared to EIH, including Apold1 (Verg), Bmp4,
Cebpd, Cxcl1,Cyr61, Dio2, Fst, Has1, Lbp, and Sectm1b,
were further evaluated using RT-PCR. RT-PCR analysis,
using a larger sample size (n = 7 to 8), determined that
there was a 2-fold or more increase with AMPH com-
pared to EIH in Bmp4, Dio2, Lbp, and Sectm1b at 3 hr
(Table 7). One day Lbp levels were 4- and 8 -fold greater
than the control Lbp at the 3 hr time point. Array analysis
Table 4 Relative mRNA expression of experimental treatments at 3 hr for genes involved in adherin junctions, tight
junctions, or angiogenesis
NCBI gene symbol AMPH compared to control EIH compared to control AMPH compared to EIH
MAV Choroid plexus MAV Choroid plexus MAV Choroid plexus
Ocln 0.36 1.17a 0.67 1.21a 0.54 0.96a
Cldn1 0.86 1.04a 0.97 1.18a 0.88 0.88a
Cldn3 1.22 1.02 0.99 0.88 1.23 1.16
Cldn4 1.50 0.77 1.60 1.00 0.94 0.78
Cldn5 0.41a 0.32 0.59a 0.48 0.69a 0.66
Cldn11 0.88 0.48 0.81 0.77 1.09 0.62
Magi2 0.90 0.51 1.16 0.88 0.77 0.58
Magi3 0.74 1.01 1.08 1.07 0.69 0.94
Esam 2.07b 1.92 1.14 1.85 1.85a 1.04
F11r (Jam1) 0.73a 1.09 0.69a 0.94 1.06a 1.16
Jam2 0.67 0.97 0.96 0.92 0.70 1.05
Jam3 0.77 0.77 0.84 0.71 0.91 1.09
Cdh5 0.92 0.87 1.03 1.41 0.90 0.62
Aqp4 0.76a 0.52 1.05b 0.66 0.73a 0.78
Slc2a1 1.39 0.82 1.13 1.04 1.24 0.79
Angpt2 1.02a 1.12 1.02a 1.21 1.00a 0.66
Tek 0.43 0.88 0.62 1.38 0.69 0.64
Ctnnb1 1.29 0.74 0.83 0.68 1.56 1.09
Pdgfrb 0.60 0.60 0.86 0.95 0.70 0.63
Sox18 0.33a 0.70 0.67a 0.70 0.50a 1.01
Agrn 0.70 0.81 0.77 0.70 0.91 1.15
Bold text indicates genes that were significantly differentially expressed (FDR = 0.10) between treatment comparisons.
a Array expression results were confirmed with RT-PCR.
b Array expression results were not confirmed with RT-PCR.
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0.20) to be significantly differentially affected by AMPH
compared to EIH at 1 day. The Nat3 increase was poten-
tially the most significantly affected by AMPH relative to
EIH at 1 day by array analysis but RT-PCR analysis failed
to verify this finding. RT-PCR was not used to verify
Angel2 and Arsk expression since there was less than a
1.5-fold (AMPH/EIH) change for both genes. Additionally,
RT-PCR analysis indicated that Lbp expression in AMPH
was 2-fold higher at the 1 day time point compared to
EIH but the difference was not found to be significant.
Discussion
New data have been presented that compares the global
gene expression (at the mRNA level) in the choroid
plexus and the MAV under control conditions and after
exposure to EIH or a neurotoxic AMPH exposure.
Under control conditions, the high degree of similarity
in the global gene expression profiles of the MAV and
choroid plexus suggests some overlap in their various
physiological roles supporting brain function [2-6,11,13],
particularly the CSF. However, basal expression of genesrelated to the BBB and other tight junctions show some
distinct differences in MAV versus choroid plexus.
Expression changes related to genes involved in oxida-
tive stress, ERSR, and the immune system indicated
that both the choroid plexus and MAV are adversely
affected by AMPH and EIH. However, the expression
response in the MAV to neurotoxic doses of AMPH
and EIH (to a lesser extent) was more pronounced than
in the choroid plexus with respect to genes controlling
vascular tone and angiogenesis. Unique genes were
found in the choroid plexus and in the MAV that give
further insight into differences between AMPH and
EIH effects and may serve as biomarkers of damage.
Comparisons of choroid plexus and MAV expression in
control
In our study, there was a high correlation of r = 0.92
between gene expression in the choroid plexus and MAV
for control animals. Furthermore, 50% of the genes that
had a 15-fold (60% for >10-fold) or greater enrichment
(compared to striatum and parietal cortex) in choroid
plexus also had a 15-fold or higher enrichment in the
Table 5 RT-PCR determination of gene expression in MAV, striatum, and parietal cortex
3 hr 1 day
NCBI gene symbol Brain Region Control AMPH EIH AMPH EIH
Angpt2 MAV 1.08 ± 0.37 0.82 ± 0.23 (0.76) 0.81 ± 0.17 (0.75) N.D. N.D.
Parietal Cortex 0.02 ± 0.004 0.04 ± 0.01 (2.00) 0.03 ± 0.01 (1.50) N.D. N.D.
Striatum 0.03 ± 0.001 0.06 ± 0.02 (2.00) 0.04 ± 0.01 (1.33) N.D. N.D.
Aqp1 MAV 6.67 ± 1.61 5.30 ± 1.89 (0.79) 5.68 ± 1.11 (0.85) N.D. N.D.
Parietal Cortex 0.01 ± 0.003 0.08 ± 0.17 (8.00) 0.02 ± 0.02 (2.00) N.D. N.D.
Striatum 0.02 ± 0.003 0.04 ± 0.01 (2.00) 0.02 ± 0.003 (1.00) N.D. N.D.
Aqp4 MAVb,c 1.00 ± 0.34 1.11 ± 0.27 (1.11) 1.74 ± 0.11 (1.74) N.D. N.D.
Parietal Cortex 0.75 ± 0.03 0.73 ± 0.12 (0.97) 0.79 ± 0.10 (1.05) N.D. N.D.
Striatum 1.86 ± 0.01 2.14 ± 0.24 (1.15) 2.01 ± 0.36 (1.08) N.D. N.D.
Cldn5 MAVa 3.95 ± 1.18 0.99 ± 0.52 (0.25) 1.53 ± 0.88 (0.39) N.D. N.D.
Parietal Cortex 0.41 ± 0.06 0.19 ± 0.05 (0.46) 0.19 ± 0.12 (0.46) N.D. N.D.
Striatum 0.45 ± 0.04 0.20 ± 0.06 (0.44) 0.28 ± 0.13 (0.62) N.D. N.D.
Esam MAV 3.55 ± 1.16 4.29 ± 1.19 (1.21) 2.68 ± 0.42 (0.75) N.D. N.D.
Parietal Cortex 0.25 ± 0.03 0.66 ± 0.14 (2.64) 0.68 ± 0.42 (2.72) N.D. N.D.
Striatum 0.35 ± 0.02 0.80 ± 0.21 (2.29) 0.55 ± 0.04 (1.57) N.D. N.D.
F11r MAVa,b 1.63 ± 0.27 0.96 ± 0.15 (0.59) 0.96 ± 0.20 (0.59) N.D. N.D.
Parietal Cortex 0.11 ± 0.02 0.10 ± 0.01 (0.91) 0.10 ± 0.03 (0.91) N.D. N.D.
Striatum 0.19 ± 0.02 0.15 ± 0.01 (0.79) 0.16 ± 0.05 (0.84) N.D. N.D.
Fst MAVa,d 0.11 ± 0.05 2.23 ± 1.33 (20.27) 0.33 ± 0.15 (3.00) 0.25 ± 0.16 (2.78) 0.09 ± 0.02
Parietal Cortex 0.11 ± 0.05 0.21 ± 0.06 (1.91) 0.22 ± 0.04 (2.00) N.D. N.D.
Striatum 0.19 ± 0.05 0.40 ± 0.20 (2.10) 0.33 ± 0.04 (1.74) N.D. N.D.
Has1 MAVa,d 0.05 ± 0.02 0.20 ± 0.08 (2.0) 0.760 ± 0.670 (15.20) 0.21 ± 0.07 (1.75) 0.12 ± 0.02
Parietal Cortex 0.04 ± 0.01 0.11 ± 0.03 (2.75) 0.13 ± 0.04 (3.25) N.D. N.D.
Striatum 0.03 ± 0.01 0.07 ± 0.03 (2.33) 0.06 ± 0.01 (2.00) N.D. N.D.
Lbp MAVd 2.22 ± 0.86 3.52 ± 2.43 (1.58) 1.40 ± 0.48 (0.63) 12.05 ± 7.42 (5.06) 2.38 ± 1.12
Reg3a MAVa,d 0.001 ± 0.001 0.45 ± 0.50 (450.00) 0.01 ± 0.01 (10.00) N.D. N.D.
Parietal Cortex 0.001 ± 0.001 0.002 ± 0.001 (2.00) 0.005 ± 0.00 (5.00) N.D. N.D.
Striatum 0.01 ± 0.01 0.02 ± 0.01 (2.00) 0.03 ± 0.004 (3.00) N.D. N.D.
Reg3b MAVa,d 0.001 ± 0.001 0.21 ± 0.27 (210.00) 0.01 ± 0.004 (10.00) 0.44 ± 0.36 (62.86) 0.007 ± 0.014
Parietal Cortex 0.001 ± 0.00 0.001 ± 0.00 (1.00) 0.001 ± 0.00 (1.00) N.D. N.D.
Striatum 0.0005 ± 0.0001 0.0007 ± 0.0002 (1.40) 0.0005 ± 0.0003 (1.00) N.D. N.D.




















Table 5 RT-PCR determination of gene expression in MAV, striatum, and parietal cortex (Continued)
Sct MAVa,d 0.004 ± 0.001 0.025 ± 0.017 (6.25) 0.006 ± 0.002 (1.50) 0.014 ± 0.004 (3.50) 0.004 ± 0.002
Slc15a1 MAVa,c 0.19 ± 0.09 3.19 ± 5.72 (16.79) 0.16 ± 0.07 (0.84) 0.04 ± 0.04 (1.33) 0.03 ± 0.02
Parietal Cortex 0.03 ± 0.003 0.04 ± 0.01 (1.33) 0.03 ± 0.003 (1.00) N.D. N.D.
Striatum 0.04 ± 0.01 0.05 ± 0.01 (1.25) 0.04 ± 0.01 (1.00) N.D. N.D.
Sox18 MAVa 5.57 ± 2.58 0.96 ± 0.33 (0.17) 2.11 ± 1.54 (0.38) N.D. N.D.
Parietal Cortex 0.36 ± 0.06 0.17 ± 0.07 (0.47) 0.24 ± 0.20 (0.67) N.D. N.D.
Striatum 0.46 ± 0.10 0.23 ± 0.08 (0.50) 0.26 ± 0.25 (0.56) N.D. N.D.
All genes are expressed as a percentage of Gapdh and are shown as the mean plus/minus standard error of the mean. Fold-changes of treatment to control are given in parentheses at the 3 hr time point. At the 1 day time
point, fold-changes (in parentheses) are expressed as AMPH to EIH. All the RT-PCR primers appeared to function optimally except those for Slc15a1 which gave a somewhat bimodal melt curve (several sets of primers were
tried). The number of RNA aliquots (one per animal) used to determine expression per treatment group were as follows: 3 hr control, n = 6; 3 hr AMPH, n = 7; 3 hr EIH, n = 6; 1 day AMPH, n = 6; 1 day EIH, n = 6.
N.D. designates expression not determined.
Symbols indicating statistically significant difference between treatments are found as a superscript after the brain region (second column).
a AMPH significantly differs from control at 3 hr (p < 0.05).
b EIH significantly differs from control at 3 hr (p < 0.05).
c AMPH significantly differs from EIH at 3 hr (p < 0.05).




















Table 6 Genes with significant differential expression between AMPH and EIH at 3 hr in MAV
NCBI gene
symbola
AMPH/EIH Specific gene function General function Reference
A3galt2 2 T-cell function? NCBI Entrez Gene
Abca1 2.18 ATP-binding cassette (ABC) transporters Cholesterol transport NCBI Entrez Gene
Actn3 2.47 Cross links actin containing filaments NCBI Entrez Gene
Ada 0.41 Adenosine deaminase Immune system – modulates lymphocyte activity? NCBI Entrez Gene
Adamts9 2.97 Metalloproteinase inhibitor Vascular Function - angiogenesis? PMID: 19052845
Akr1b8 4.49 Unknown Carcinogen-dependent tumor-associated protein NCBI Entrez Gene
Asns 2.22 Asparagine synthesis Cell growth and differentiation – blocks cell proliferation NCBI Entrez Gene
Bzw2 2.04 Transcription factor? NCBI Entrez Gene
Cd14 3.14 Binds bacterial lipopolysaccharides Cell surface protein that mediates monocyte
responses to bacterial lipopolysaccharides
NCBI Entrez Gene
Cd93 1.75 Immune system function? NCBI Entrez Gene
Cyp1b1 2.61 Cytochrome P450 monooxygenases Lipid metabolism -polycyclic aromatic hydrocarbon,
steroid metabolism or phospholipids metabolism
NCBI Entrez Gene
Egfr 2.01 Epidermal growth-factor receptor Cell growth and differentiation NCBI Entrez Gene
Eif2b3 1.75 Subunit of initiation factor eIF2B NCBI Entrez Gene
Emp1 1.88 Epithelial membrane protein 1 NCBI Entrez Gene
Enpp3 3.10 Hydrolysis of extracellular nucleotides Unknown - Found in immature glia, gut and pancreas NCBI Entrez Gene
Fcgr3 1.86 Receptor on Fc portion of IgG Immune system function NCBI Entrez Gene
Fgl2 3.11 Regulates thrombosis Vascular endothelium regulation of thrombosis PMID: 15100314
Fmo5 4.03 N-oxidation of amino-trimethylamine Fmo5 not well characterized NCBI Entrez Gene
Foxj1 0.41 Unclear in mammals Unknown – characterization incomplete NCBI Entrez Gene
Fstb 6.64 Can Inhibit vesicular release of FSH Adipogenesis? Cancer? NCBI Entrez Gene
PMID19470636
Gda 2.53 Hydrolytic deamination of guanine Cell signaling? – incomplete characterization NCBI Entrez Gene
Gja5 2.57 Endothelial gap junction protein Vascular function - structural integrity NCBI Entrez Gene
Gpr4 2.20 GCP receptor for lysophosphatidylcholine May mediate monocyte transmigration through endothelial NCBI Entrez Gene,
PMID17364894
Has1b 7.20 Regulates the biosynthesis of hyaluronan Immune System - inflammation related? PMID: 17611197
Ilr2* 5.48 Interleukin 1 receptor family Inhibits the activity of Il-1 NCBI Entrez Gene
Ilrn* 3.35 Binds to Interleukin 1 receptor Inhibits the effects of IL-1 NCBI Entrez Gene
Itpkc 2.21 Phosphorylates inositol triphosphate NCBI Entrez Gene
Lbp 4.15 Binds LPS and interacts with the CD14
receptor
Acute-phase immunologic response to gram-negative
bacterial infections
NCBI Entrez Gene
Lrrc4c 0.38 Lrrc4c (NGL1) is a specific binding
partner for netrin G1
Has been implicated in axonal guidance NCBI Entrez Gene
Llgl1 2.14 Non-muscle myosin II heavy chain and a kinase associated NCBI Entrez Gene
Mt1ab 2.77 Protects against oxidative stress Cardiovascular function - protection from ROS in diabetes? PMID: 18249147
PMID: 18349110
Mthfd1l 1.94 Synthesis of tetrahydrofolate in
the mitochondrion
NCBI Entrez Gene
Ndrg1 2.21 Cytoplasmic protein involved in stress Involved in endothelial cell migration PMID: 19760510
Nef3 0.45 Medium neurofilament protein Biomarker of neuronal damage NCBI Entrez Gene
Nnij1 1.67 Nerve injury associated protein NCBI Entrez Gene
Ogfrl1 1.93 Opioid growth factor receptor-like 1 NCBI Entrez Gene
Olfm3 0.42 Associated with lung cancer NCBI Entrez Gene
Pmp22 1.79 Component of myelin in the peripheral nervous system NCBI Entrez Gene
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Table 6 Genes with significant differential expression between AMPH and EIH at 3 hr in MAV (Continued)
Pstpip1 1.76 Immune system-related NCBI Entrez Gene
Ptprj 1.89 Protein tyrosine phosphatase Cell cycle and differentiation NCBI Entrez Gene
Ptges 3.02 Synthesized PGE2 Vascular Function - vasodilatation NCBI Entrez Gene
Ramp3 2.97 Calcitonin receptor modulating protein Angiogenesis and vascular integrity PMID: 18097473
Reg3a 23.49 Extracellular matrix repair? Inflammation – expressed in pancreatitis and liver
cancer damage - function unknown in MAV
NCBI Entrez Gene
Reg3b 27.01 Extracellular matrix repair? Inflammation – related to pancreatic damage - function
unknown in MAV
PMID: 19077460
Reg3g 8.29 Extracellular matrix repair? Inflammation – related to pancreatic damage and
development - function unknown in MAV
NCBI Entrez Gene
Rrp9 1.77 Processing of 18 s rRNA during ribosome synthesis NCBI Entrez Gene
Rsad2 2.27 Bone formation? NCBI Entrez Gene
Sct 4.93 Induces gastric relaxation Endocrine hormone in pancreas and gut – function in
MAV may be stimulate bicarbonate secretion
NCBI Entrez Gene
Slc15a1 33.90 Hydrogen peptide co-transporter Inflammation? – transports polypeptides in
intestine - function unknown in MAV
NCBI Entrez Gene
PMID: 19462432
Slco4a1* 1.85 Organic anion transporter NCBI Entrez Gene
Slpi* 6.58 Protects epithelial tissues from serine proteases NCBI Entrez Gene
Timp1 2.60 Metallopeptidase inhibitor Multiple functions some vascular-related NCBI Entrez Gene
Tmem2 2.72 Membrane spanning protein? Unknown- characterization incomplete NCBI Entrez Gene
Tmem63c 2.02 Membrane spanning protein? Unknown- characterization incomplete NCBI Entrez Gene
Wnt4 1.73 Cell signaling and development NCBI Entrez Gene
PMID: denotes the Pub Med ID if a particular publication has been primarily used to determine specific and general gene functions.
a All listed genes were differentially affected by AMPH compared to EIH (FDR = 0.10). Also, genes with very high expression in blood (data not shown) are
excluded from this table as well as genes which were previously reported to be affected [24,25].
b Relative to control, both EIH and AMPH significantly increased expression.
* Indicates some expression may be due to residual blood in MAV.
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functional capabilities. Over 70% of the overlapping highly
expressed genes between choroid plexus and MAV could
be categorized into groups involved in: 1) extracellular
matrix and cell-cell junctions, 2) development and
transcription regulation, 3) ion and solute transport and
homeostasis, 4) vasculature and heart, and 5) immune sys-
tem (Table 1 and Additional file 2: Table S2). The majority
of the rest of the genes were lumped into an unknown
and miscellaneous category. Since 50% of these genes have
an unknown function, the percentage of genes actually in
the top 5 categories could be as high as 85%. The MAV
contained many more genes in the retinoic acid & lipid
processing category than did the choroid plexus.
Many of the highly expressed genes identified in the
MAV that are placed in the ion and solute transport
category may play a role in the pial and arachnoid
membrane function of the MAV. Many of these genes are
also expressed highly in the choroid plexus and therefore
could play a role in ion and solute composition regulation
of CSF (Table 1 and Additional file 2: Table S2). Genes
highly expressed in the MAV and choroid plexus that
are related to water, ion, and solute homeostasis include
the water channel Aqp1 [41], the sodium bicarbonateco-transporter Slc4a5 [42], the chloride/bicarbonate
exchanger Slc26a7 [43], the potassium inwardly-rectifying
channel Kcnj13 [44], the organic anion transporter Slco1a5
[45], and two transporters that appear to be related to
the regulation of thyroid function, solute carrier family 5,
sodium iodide symporter, member 5 (Slc5a5 [46] and
transthyretin (Ttr)) [47]. Most of these genes have also
been previously identified in the epithelial cells of the
kidney, pancreas, lung, and placenta.
Many genes with relatively high expression in the MAV
(e.g., annexin A1, Anxa1 [48]; annexin A2, Anxa2 [46];
major histocompatibility complex class II invariant chain
Cd74 molecule, Cd74 [49]; lectin galactoside-binding sol-
uble 1, Lgals1, [50]; defensin beta 1, Defb1 [51]; chemokine
(C-X-C motif) ligand 14, Cxcl14 [52]) were identified as
important for endothelial cell interactions with myeloid or
lymphoid interactions, and could be involved in regulating
myeloid and lymphoid cell responses and trafficking in the
MAV vasculature and/or the CSF. This suggests that
under control conditions the immune surveillance and
other functions in the MAV are possibly more extensive
than in the cortex and striatum and probably most of the
remaining forebrain. Of the remaining genes with relatively
high expression in the MAV and choroid plexus, most were
Table 7 RT-PCR determination of gene expression in the choroid plexus
3 hr 1 day
NCBI gene symbol Control AMPH EIH AMPH EIH
Apold1(Verge)a 0.03 ± 0.002 0.06 ± 0.02 (2.00) 0.06 ± 0.07 (2.00) N.D. N.D.
Bmp4a,c 0.55 ± 0.04 3.65 ± 1.26 (6.64) 0.84 ± 0.23 (1.53) N.D. N.D.
Cebpd a,b 0.01 ± 0.003 0.24 ± 0.09 (24.00) 0.15 ± 0.13 (15.00) N.D. N.D.
Cldn1 5.74 ± 0.70 5.73 ± 0.98 (1.00) 6.49 ± 0.80 (1.13) N.D. N.D.
Cxcl1 a,b 0.004 ± 0.002 0.40 ± 0.62 (100.00) 0.30 ± 0.51 (75.00) N.D. N.D.
Cyr61 a,b 0.24 ± 0.06 3.54 ± 2.70 (14.75) 3.16 ± 5.10 (13.17) N.D. N.D.
Dio2 a 0.01 ± 0.005 4.34 ± 2.03 (434.00) 1.08 ± 1.13 (108.00) N.D. N.D.
Edn1b 0.003 ± 0.001 0.005 ± 0.002 (1.67) 0.011 ± 0.010 (3.67) 0.003 ± 0.004 (1.50) 0.002 ± 0.000
Fst b,d 0.03 ± 0.02 0.06 ± 0.02 (2.00) 0.10 ± 0.06 (3.33) 0.03 ± 0.02 (3.00) 0.01 ± 0.003
Has1 a,b 0.09 ± 0.06 0.17 ± 0.03 (1.89) 0.17 ± 0.02 (1.89) 0.11 ± 0.02 (1.10) 0.10 ± 0.02
Lbp a 0.11 ± 0.06 0.53 ± 0.32 (4.81) 0.24 ± 0.12 (2.18) 0.97 ± 0.57 (2.11) 0.46 ± 0.31
Nat3 b 0.01 ± 0.004 0.01 ± 0.004 (1.00) 0.01 ± 0.008 (1.00) 0.004 ± 0.003 (0.50) 0.008 ± 0.010
Nos3 0.06 ± 0.03 0.09 ± 0.04 (1.50) 0.10 ± 0.06 (1.67) 0.08 ± 0.05 (1.33) 0.06 ± 0.01
Ocln a 4.96 ± 0.52 7.24 ± 1.12 (1.46) 6.01 ± 1.76 (1.21) N.D. N.D.
Reg3b N.E. N.E. N.E. N.E. N.E.
Sct N.E. N.E. N.E. N.E. N.E.
Sectm1b a 0.01 ± 0.002 0.46 ± 0.15 (46.00) 0.15 ± 0.14 (15.00) N.D. N.D.
All genes are expressed as a percentage of Gapdh, and are shown as the mean plus/minus standard error of the mean. Fold-changes of treatment to control are
given in parentheses at the 3 hr time point. At the 1 day time point, fold-changes (in parentheses) are expressed as AMPH to EIH. The number of RNA aliquots
(two to three animals per aliquot) used to determine expression per treatment group were as follows: 3 hr control, n = 7; 3 hr AMPH, n = 7; 3 hr EIH, n = 7; 1 day
AMPH, n = 8; 1 day EIH, n = 7.
N.E. means gene not expressed (mean Ct value > 35).
N.D. designates expression not determined.
Symbols indicating statistically significant difference between treatments are found as a superscript after the gene name (first column).
a AMPH significantly differs from control at 3 hr (p < 0.05).
b EIH significantly differs from control at 3 hr (p < 0.05).
c AMPH significantly differs from EIH at 3 hr (p < 0.05).
d AMPH significantly differs from EIH at 1 day (p < 0.05).
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However, except for possibly those genes involved in the
insulin-like growth factor pathways, it is not clear what the
exact transcription regulatory role of these genes is in the
MAV and choroid plexus. Also, it is not clear whether the
translation products of all these genes play a role in just
MAV and choroid plexus development and function or
whether some are “released” into the CSF to affect other
regions of the brain.
There were twice as many genes (17 versus 8) grouped
in the retinoic acid and lipid processing category in the
MAV versus the choroid plexus, but the significance of
this finding is not clear. There is an even more disparate
distribution of genes related to the BBB and tight junc-
tions in the choroid plexus versus the MAV. Even when
the 5- to 10-fold greater levels of vasculature present in
MAV are taken into account, its levels of BBB-related
genes (determined from [53]) were somewhat similar to
that of striatum and parietal cortex. The exceptions are
Cldn3, Tjp2 (ZO-2), and Aqp4, which may have lower
expression levels in the MAV than expected. Thus, it
appears that a BBB-related structure is also present inthe vasculature of the MAV. The presence of a BBB-like
barrier in the MAV would not only protect the surface
of the cortex from small molecules and ions present in
the blood, but it would also prevent them from leaking
into the cerebral spinal fluid and altering its composition.
Tight-junction and some BBB-related gene expressions
are present in the choroid plexus but differ from the brain
proper [6,8]. Our expression data indicates that Ocln,
Cldn1, Cldn3, Cldn9, Crb3, Tjp-3, F11r (Jam1), and Jam3
would be some of the more important genes involved in
choroid plexus tight-junctions.
Effects of AMPH and EIH on gene expression in choroid
plexus compared to MAV
Gene expression responses to the adverse effects of EIH
and AMPH differed to some extent between the MAV and
choroid plexus. In the choroid plexus, genes regulating
vascular tone, such as Nos3, Edn1, and Vip, were not
significantly affected by AMPH or EIH but they were
greatly altered in the MAV [24]. However, Adora1a and
Adora1b were elevated in choroid plexus, but not the
MAV, and may affect vasodilatation in response to AMPH
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angiogenesis (e.g., Ctgf and Timp) were significantly
increased by AMPH and EIH in the choroid plexus, just as
they were in MAV. However, other genes involved in
angiogenesis that were decreased in the MAV by AMPH
(Akt1, Anpep, Mmp2, Mmp14, and Mmp16) were not
significantly affected in the choroid plexus. On the other
hand, genes related to protein processing such as heat-
shock proteins, protein disulfide isomerases, and the ERSR
responded very similarly to AMPH and EIH in the choroid
plexus and MAV.
We have placed particular emphasis on evaluating
expression changes related to the BBB since loss of BBB
integrity can have severe damaging effects on the brain
[20-23]. With respect to genes related to BBB and tight
junctions, there were differences in response to AMPH
and EIH between the choroid plexus and MAV.
Occludin and the claudins are integral membrane pro-
teins, components of tight junction strands, and are ne-
cessary for proper BBB development and integrity
[54,55]. Our data show that in the MAV, both Ocln and
Cldn5 are well expressed and down regulated significantly
by EIH and even more so by AMPH. However, in the
choroid plexus, Ocln expression was slightly increased by
AMPH. Although Cldn5 expression was down regulated
in the choroid plexus, its constitutive expression levels, as
well as Cldn11, were very low. Also, F11r (Jam1) and
Jam2, which are key components regulating BBB [56-58],
were significantly decreased by both EIH and AMPH in
the MAV but were not significantly affected in choroid
plexus. Overall, AMPH and EIH had a more disruptive
effect on BBB/tight junction gene expression in the MAV
than in the choroid plexus. It is not clear whether this is
the result of the temporary suspension of angiogenesis
during the insult by AMPH and EIH, which may be a
protective response if short in duration.
The genes in the MAV with the largest expression
increases resulting from AMPH exposure were somewhat
unexpected since they do not appear to be directly related
to vasculature but rather to damage, inflammation, or
infection in other organs such as pancreas. These genes
include Reg3a, Reg3b, Reg3g, Slc15a1, Sct, Fst, and Lbp,
and are potential biomarkers for the damaging effects of
AMPH in MAV since they are affected to a much lesser
extent by EIH. Reg3a, Reg3b, Reg3g, and Lbp expression
increases are as, or even more, pronounced at 1 day than
at 3 hr after AMPH. The three regenerating genes Reg3a,
Reg3b, and Reg3g are particularly intriguing since they are
associated with repair and regeneration of pancreatic
tissue [59]. Reg3a, Reg3b and Reg3g are also involved in
anti-bacterial function in intestinal epithelial cells [60] and
could be involved in repairing AMPH-induced damage in
the MAV. The tremendous increase observed in the
expression in the regenerating genes, Slc15a1, Sct, and Fstafter AMPH in the MAV was not observed in the choroid
plexus. Increases are seen in Lbp expression after AMPH
(but very little with EIH) in both the MAV and choroid
plexus at 3 hr and 1 day. These changes are also particularly
intriguing since Lbp expression and protein function is
relevant to infection and damage. Together with the bac-
tericidal permeability-increasing protein (BPI), the encoded
protein binds LPS and interacts with the CD14 receptor,
which probably plays a role in regulating LPS-dependent
monocyte responses [61]. Exactly why the increase in Lbp
gene expression occurs primarily with AMPH but not EIH
is unknown. Increases in the AMPH-induced Lbp gene
expression are more pronounced in MAV compared to
choroid plexus and are reflective of AMPH producing a
much greater effect on genes related to infection and
inflammation than does EIH.
Bone morphogenic protein 4 (Bmp4) and to a lesser
extent secreted and transmembrane protein 1A and 1B
(Sectm1b) were the only genes that had a greater change
(increase) in expression in the choroid plexus after
AMPH but not after EIH. Not much is known about
Bmp4 effects on the choroid plexus so it is unclear
whether this effect would be beneficial. On the other
hand, if the protein product were to be secreted into the
lateral ventricles, it would likely suppress the progenitor
cells present and possibly be detrimental to differentiated
neurons and glia surrounding the ventricles [60,62,63].
Little is known as to what Sectm1b increases would trans-
late to in the choroid plexus because very little is known
about this gene in rodents and its homolog in humans.
Nonetheless, its 40-fold mRNA increase in choroid plexus
after the AMPH treatment would likely have some effect if
it leads to significant protein increases.
Conclusions
The comparison of gene expression data in the striatum
and parietal cortex, which are two neuronal-rich regions
of the brain, to that of the MAV and the choroid plexus
under control conditions resulted in a list of more than
100 genes with a much higher expression (15-fold or more)
in both the choroid plexus and MAV than in the two
neuronal-rich regions. There is a 50% overlap between the
highly expressed genes in the choroid plexus with those in
the MAV, suggesting an analogy in some of the various
physiological functions that the choroid plexus and MAV
play in supporting brain function [2-6,26,28], in particular
those related to the regulation of ion, solute, and immune
processes involving CSF. The global gene expression pro-
file in the MAV indicates that genes related to or regulating
tight junctions are important to its vasculature function
and to help maintain BBB integrity within the brain.
Although EIH affects genes related to the ERSR pathways
and ROS in the MAV, it has a less pronounced effect than
AMPH on genes involved in ion and solute transport, lipid
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Changes in the expression in genes related to vascular
tone, angiogenesis, BBB-related and immune-related genes
indicate that the adverse vascular effects of AMPH are
somewhat more pronounced in the MAV than they are in
the choroid plexus. The gene expression changes evoked
by AMPH or EIH appear to depict the homeostasis of
blood flow and CSF needed to prevent or repair damage
in the MAV and choroid plexus.Methods
Animals and experimental design
In brief, 75 to 90-day-old male Sprague–Dawley rats
were obtained from the breeding colony of the National
Center for Toxicological Research (NCTR). The studies
were carried out in accordance with the declaration of
Helsinki and the Guide for the Care and Use of Laboratory
Animals as adopted and promulgated by the National
Institutes of Health. AMPH and EIH exposures were
similar to that of Bowyer et al. [64] and the overall dosing
and experimental design was modeled after previous work
[24,25]. Oligo array and RT-PCR data for the choroid
plexus was generated in this study; however, a portion of
the oligo array data for MAV was presented in Thomas
et al. [25]. Rats were housed two per cage until three days
prior to AMPH exposure, with food and water available
ad libitum, and were on a daily 12-hr light–dark cycle,
with lights on 6:00 a.m. Temperature and humidity were
controlled at 23°C and 53%, respectively. During exposure
to AMPH, rats were housed one per cage to facilitate
behavioral observations without inter-animal interactions.
Dosing commenced between 7:30 and 8:00 a.m. and the
D-amphetamine sulfate (Sigma-Aldrich, St. Louis, MO,
USA) was dissolved in normal saline prior to injection.
Control animals received normal saline alone at the same
volumes. All doses were administered subcutaneously.
The rectal temperature was monitored every hour in all
animals for at least 8 hr after the start of dosing. Details of
body temperature monitoring and overall experimental
design can be found in Thomas et al. [24,25].Rats dosed for generating RNA for MAV oligo array analysis
Total RNA for oligo array analysis of MAV gene expression
was generated in our previous two studies [24,25]. In these
studies, 15 rats were administered four doses of 1 ml/kg
normal saline with 2 hr between each dose. Four were given
saline at a 24°C room temperature and remained at normal
body temperature during body temperature monitoring
(normothermic group). Eleven animals were given saline in
a 39° to 40°C environment (EIH group, 10 rats survived)
and had a hyperthermic profile very similar to the rats
given AMPH. Seventeen rats were given four doses of
AMPH comprised of a sequential exposure to 5, 7.5,10 and 10 mg/kg AMPH with 2 hr between each dose
(15 rats survived).
Rats dosed for generating RNA for choroid plexus oligo
array and RT-PCR analysis
In order to carry out the oligo array analysis for the choroid
plexus data and RT-PCR verification of MAV and choroid
plexus mRNA expression levels, an additional 65 animals
were dosed specifically for the present study with saline
under normothermic conditions (n = 13), saline under EIH
conditions (n = 24), or AMPH (n = 28). The trunk blood
from these animals was also subjected to oligo array
analysis. Blood expression data was used only to deter-
mine which genes were present at much higher levels
(5-fold or greater) under control conditions in blood
compared to MAV and choroid plexus. Such genes
were excluded from analysis in MAV and choroid
plexus since the expression levels could have been
greatly affected by the residual blood present in MAV
and choroid plexus.
Sacrifice and tissue harvest for oligo array data collection
Rats were given an overdose of 300 mg/kg body weight
of pentobarbital resulting in deep anesthesia in less than
3 min and were then killed by decapitation. Their brains
were then rapidly, but carefully, removed and chilled in
ice-cold normal saline for 5 min. The arachnoid and pial
membranes of the meninges and associated vasculature
surrounding the forebrain were then dissected away from
the brain surface (MAV tissues). For all animals used in
this study, the parietal cortex, followed by the choroid
plexus and striatum were dissected bilaterally on ice and
saved for analysis as previously described [24,39].
The array analysis for MAV, striatum, and parietal
cortex was performed on total RNA obtained from animals
sacrificed in previous work [14,15], with the exception that
RNA from one additional animal sacrificed 3 hr after
AMPH was added and one less 3 hr EIH sample was
available (RNA was depleted by previous RT-PCR studies)
[24,25]. Thus, the number of RNA aliquots from individual
animals at 3 hr after the final dose was n = 4 for saline at
room temperature, n = 4 for EIH, and n = 7 for AMPH.
The number of RNA aliquots from individual animals at
1 day after the final dose was n = 5 for EIH and n = 8 for
AMPH. For the choroid plexus oligo array and RT-PCR
analysis, we used tissue from 15 to 21 rats for each of the
five treatment groups in the study (saline 3 h, EIH 3 h,
AMPH 3 h, EIH 1d, and AMPH 1d). Unlike the MAV,
RNA from choroid plexus was pooled from two to three
animals for each aliquot (n = 1) tested. This was done
because of the very small amount of choroid plexus tissue
that can be harvested from an individual rat (1.5 to
2.0 mg/rat). The pooling resulted in 5 to 7 final separate
RNA aliquots to be analyzed by RT-PCR (all aliquots) and
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of the experimental groups and animal IDs used for oligo
array analysis can be found in GSE23093 (MAV, striatum,
and parietal cortex) and GSE29733 (choroid plexus) at the
NCBI GEO repository. Note that RNA sample pools, in
addition to those listed for MAV and choroid plexus in the
NCBI GEO files, were used for the RT-PCR analysis of
expression in these brain regions.
RNA isolation and oligonucleotide array analysis
Tri Reagent (Molecular Research Center Inc., Cincinnati,
OH) [65] was used to isolate total RNA with modifications
similar to those previously described [24,25]. The final total
cellular RNA concentrations (in RNase-free water, 1 mM
EDTA) for MAV and choroid plexus ranged from 1.3 to
2 μg/μl, while those of the striatum and parietal cortex
ranged from 2.5 to 4.0 μg/μl. The isolated RNA was stored
at −70°C until amplification for oligo array analysis.
Changes in gene expression were evaluated from total
RNA using the Agilent One-Color Microarray-Based Gene
Expression Platform. For hybridization onto Agilent-
014879 Whole Rat Genome 4 × 44 K 60mer oligonucleo-
tide arrays (G4131F, Agilent Technologies, Palo Alto, CA;
NCBI GEO Accession # GPL7294), 500 ng of total RNA
was used in the Agilent Quick Amp Labeling Kit (5190–
0442) according to the manufacturer's instructions.
As mentioned above, total RNA from individual animals
was used for array hybridization (no pooling of samples)
for the MAV, striatum, and parietal cortex. Five groups
were evaluated, but only four individual animals could be
analyzed per slide. To facilitate comparisons and reduce
normalization variability, the first five of the 4 × 44 K slides
groups were sequentially rotated so that 4 animals in all 5
groups were evaluated. The remaining EIH and AMPH an-
imals needing evaluation were run on the next four slides,
each of which contained one normothermic control and
selected repeats of previously (first five slides) analyzed
samples. A total of nine 4 × 44 K array slides for expression
analysis were used for each region (27 slides total). This
was done to aid in array normalization and to ensure that
minimal variability occurred in expression results across all
nine slides. There was minimal variability between dupli-
cate control or treatment arrays, however, in our statistical
analysis duplicates were not averaged because this could
not be done for the AMPH groups. The same platform
and very similar methods were followed to analyze the
pools of RNA (two to three rats per pool) derived from the
choroid plexus, except that the control pools were not run
in duplicate. Five 4 × 44 K array slides were used for gene
expression analysis of the choroid plexus.
Total RNA was reverse transcribed into complemen-
tary DNA (cDNA) using T7-promotor primer and
MMLV reverse transcriptase. The cDNA was transcribed
into complimentary RNA (cRNA), during which it wasfluorescently labeled by incorporation of cyanine (Cy)
3-CTP. After purification, using the RNeasy mini kit
(Qiagen), cRNA yield and Cy3 incorporation efficiency
(specific activity) into the cRNA were determined using
a NanoDropW ND-1000 Spectrophotometer (NanoDrop
Technologies). All cRNAs had a yield >5 μg and a specific
activity of 8–15 pmol/μg. For each sample, a total of
1.65 μg cRNA was fragmented and hybridized onto
an Agilent 4 × 44 K oligonucleotide microarray in a
hybridization oven at 65°C for 17 hr using the Agilent Gene
Expression Hybridization Kit (5188–5281). The hybridized
microarrays were disassembled at room temperature in
Gene Expression Wash Buffer 1 (5188–5325) and then
washed in Gene Expression Wash Buffer 1 at room
temperature for 1 min. This was followed by a wash for
1 min in Gene Expression Wash Buffer 2 (5188–5326) at
an elevated temperature (≈31°C) and air drying. To pre-
serve the fluorescent signal intensity on the microarrays
from degradation of the Cy3 dye due to environmental
ozone, the entire disassembly and washing procedure was
conducted in a low-ozone laboratory (~1 ppb ozone), with
the final drying step and scanning conducted inside a
low-ozone biobubble (<1 ppb ozone). The arrays were
scanned on an Axon 4000B scanner (Molecular Devices
Corporation, Sunnyvale, CA) and further processed
using GenePix Pro 6.0 software (Molecular Devices). The
resulting text files were uploaded into the ArrayTrack
database (NCTR, Jefferson, AR) for analysis. The local
background was subtracted from the fluorescence values
of each spot to obtain signal intensity values.
The working microarray dataset was obtained through
gene filtering, background correction, logbase2 (log2)
transformation, and normalization. Probes were filtered to
include only those genes with official NCBI gene symbols.
We included in our analysis each probe for genes with less
than 4 probes. For genes with 4 or more probes, we used
the average signal intensity after discarding the minimum
and maximum values. Raw expression data were corrected
for background signal. To symmetrize the distribution of
background-corrected intensity values and stabilize the
variance, we transformed the gene expression data using
log2 transformation and applied quantile normalization
[66]. Statistical significance of differential expression was
determined for all pairwise treatment comparisons within
the 3 hr and 1 day time points. Significance was determined
using the Significance Analysis of Microarrays (SAM)
method [67]. SAM computes modified gene-specific t-test
statistics and estimates the false discovery rate (FDR) using
permutation analysis with replicated samples of the expres-
sion data. The FDR [68] is a statistical method for multiple
hypothesis testing that controls the expected proportion of
false positives among all identified genes in microarray
analysis. Using SAM, we were able to identify differentially
expressed genes while controlling the false discovery rate.
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SAM with an estimated FDR of approximately 10% for each
pairwise comparison for 3 hr analysis and an FDR of
approximately 20% for the 1 day analysis. Further, the lists
of significant genes were filtered so that genes meeting the
following criteria remained: at least one of the two genes in
the pairwise comparison had an average intensity equal to
or greater than 150 and the fold-change between the two
treatments exceeded 1.3. We used the inverse of the log2
transformation to convert transformed/normalized data
back to their original domain and used these values to
report average gene intensity and fold-change.
Genes determined to be significantly different at the
3 hr and 1 day time points were analyzed using pathway
analysis through Ingenuity Pathway Analysis (IPA) soft-
ware (Ingenuity System, Inc., Redwood City, CA). The
“Core Analysis” function in IPA was used to interpret
the data in the context of biological processes, pathways,
and networks.
Quantitative RT-PCR analysis of gene expression
Aliquots of the total RNA used to generate first strand
cDNA targets were diluted to 0.4 μg RNA/μl in RNase-
free water for the reverse transcription (RT) reaction.
The RT reaction was run using the standard techniques
for use with Superscript™ III reverse transcriptase
(Invitrogen Corp., Carlsbad, CA). Random hexamers
(50 ng) were used for priming 0.8 μg of total RNA in a
10 μl reaction mixture that also contained 400 μM
dNTPs. This mixture was incubated at 65°C for 5 min
followed by 4°C for 5 min. Complementary DNA synthe-
sis was then initiated by adding 10 μl of the reaction
mixture to the priming mixture (20 μl total). The final
concentrations of reactant constituents were 20 mM
Tris–HCl (pH 8.4), 50 mM KCl, 5 mM MgCl2, 10 mM
dithiothreitol, 200 μM dNTP, 2 units/μl RNaseOUT
inhibitor, and 10 units/μl Superscript™ III reverse tran-
scriptase polymerase. The reactants were first incubated
for 10 min at 25°C, then 50°C for 50 min, followed by
85°C for 5 min. The mixture was then chilled on ice for
5 min, and 1 μl of RNase H was added to each sample
followed by 20 min incubation at 37°C. The final cDNA
product was diluted 20-fold and stored at −20°C until its
use in polymerase chain reactions (PCR).
The expression of selected genes was determined by PCR,
using iQ™ SYBRW Green Super mix (Bio-Rad Laboratories,
Hercules, CA). The SYBR Green-labeled DNA products
were amplified with 5’- and 3’-primers designed using
the NCBI Primer-BLAST software and iQ™ SYBRW
Green Super mix (Bio-Rad Laboratories, Hercules, CA),
as previously described (Bowyer et al., 2008). The
Additional file 5: Table S5 lists the genes analyzed and the
sequences of the oligonucleotide primers used. Each sample
was run in duplicate. PCR cycling conditions were set at95°C for 5 min for the first cycle and 30 seconds at 95°C
followed by 30 sec at 60°C for the remaining 40 cycles. This
was then followed by 40 repetitive cycles of 10 sec starting
at 55°C and incrementing in temperature by 0.5°C/cycle
to determine a melt curve as a means of validating the
PCR product.
Relative quantities were calculated by subtracting the
Ct values of the gene of interest from that of the
endogenous control Gapdh (NM_017008) and expressed as
a percentage of the Gapdh expression level by calculating
2-ΔCt × 100. Gapdh Ct values that were used to normalize
gene expression data can be found in the Additional file 5:
Table S5. Genes with Ct values higher than 35 were consid-
ered not expressed (below the limit of quantification). For
the 3 hr RT-PCR data, statistical significance between
treatments for each gene was determined by carrying out
the Kruskal-Wallis test followed by a multiple comparison
of adjustment. The Mann–Whitney U test was used to
analyze the difference between AMPH and EIH in the RT-
PCR 1 day data. Statistical significance was evaluated at a
5% significance level (p < 0.05).
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included within the article and its four Supplementary
Tables. The Oligo array data sets used for generating the
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